Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$1.46 USD
-0.19 (-11.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.50 +0.04 (2.74%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Neumora Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
NMRA 1.46 -0.19(-11.52%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neumora Stock Hits Record Low on Depression Drug Study Failure
Other News for NMRA
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Q2 2025 Neumora Therapeutics Inc Earnings Call Transcript
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)